Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Public ClinicalTrials.gov record NCT04142437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.
Study identification
- NCT ID
- NCT04142437
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2020
- Primary completion
- Nov 29, 2029
- Completion
- Mar 30, 2030
- Last update posted
- Jul 6, 2026
2020 – 2030
United States locations
- U.S. sites
- 51
- U.S. states
- 24
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Desert Medical Center | Mesa | Arizona | 85202 | Withdrawn |
| California Research Inst. | Los Angeles | California | 90027 | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90089 | Withdrawn |
| UCLA - Mattel Children's Hospital | Los Angeles | California | 90095 | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 82663 | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland | California | 94609 | Withdrawn |
| Stanford Univ Med Ctr. / Lucile Packard Children's Hosp | Palo Alto | California | 94304 | Recruiting |
| Providence Health System - Southern California | Santa Monica | California | 90404 | Terminated |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | 90502 | Withdrawn |
| SCL Health | Grand Junction | Colorado | 81501 | Withdrawn |
| Yale University | New Haven | Connecticut | 06520 | Recruiting |
| Mayo Clinic | Jacksonville | Florida | 32224 | Withdrawn |
| University of Miami | Miami | Florida | 33146 | Recruiting |
| Nicklaus Children's Hospital | Miami | Florida | 33155 | Recruiting |
| Nemours Children's Hospital | Orlando | Florida | 32827 | Withdrawn |
| Fort Wayne Medical Oncology Hematology | Fort Wayne | Indiana | 46804 | Recruiting |
| Regional Health Hope Center | Terre Haute | Indiana | 47802 | Withdrawn |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | Recruiting |
| Maine Health | South Portland | Maine | 04106 | Recruiting |
| Univ. of Maryland / Greenebaum Comp. Cancer Ctr. | Baltimore | Maryland | 21201 | Withdrawn |
| Johns Hopkins / Sidney Kimmel Cancer Center | Baltimore | Maryland | 21205 | Recruiting |
| Frederick Health-James M Stockman Cancer Institute | Frederick | Maryland | 21702 | Terminated |
| Tufts / Neely Cancer Center | Boston | Massachusetts | 02111 | Recruiting |
| Boston Children's / Dana Farber | Boston | Massachusetts | 02215 | Withdrawn |
| Detroit Clinical Research Center | Farmington Hills | Michigan | 48334 | Recruiting |
| Sparrow Cancer Center | Lansing | Michigan | 48912 | Recruiting |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89169 | Recruiting |
| Atlantic Hem Onc / Morristown Medical Center | Morristown | New Jersey | 07960 | Withdrawn |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | Withdrawn |
| Great Lakes Cancer Center | Buffalo | New York | 14210 | Terminated |
| Memorial Sloan Kettering Children's Cancer Center | New York | New York | 10065 | Recruiting |
| Staten Island Univ. Hospital (Northwell Health) | Staten Island | New York | 10305 | Withdrawn |
| Levine Cancer Center | Charlotte | North Carolina | 28204 | Withdrawn |
| East Carolina University / Vidant Health | Greenville | North Carolina | 27834 | Recruiting |
| Ohio State Comp. Cancer Ctr. / James Cancer Hospital | Columbus | Ohio | 43210 | Withdrawn |
| Mercy Health Youngstown | Youngstown | Ohio | 44501 | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | Recruiting |
| University of Pennsylvania (Penn Med) | Philadelphia | Pennsylvania | 19104 | Withdrawn |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | Terminated |
| Medical Univ. of South Carolina | Charleston | South Carolina | 29425 | Recruiting |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Withdrawn |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| UT Southwestern Medical Center / Children's Health | Dallas | Texas | 75390 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Intermountain Healthcare - Intermountain Medical Center | Murray | Utah | 84107 | Withdrawn |
| Univ. of Utah / Huntsman Cancer Center | Salt Lake City | Utah | 84112 | Recruiting |
| Intermountain Healthcare - Dixie Regional Medical Center | St. George | Utah | 84790 | Withdrawn |
| Seattle Children's | Seattle | Washington | 98105 | Recruiting |
| West Virginia University | Morgantown | West Virginia | 26506 | Recruiting |
| Gundersen Health System | La Crosse | Wisconsin | 54601 | Recruiting |
| SSM Health Cancer Center - Dean Medical Group | Madison | Wisconsin | 53717 | Terminated |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04142437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04142437 live on ClinicalTrials.gov.